TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter STudy to Evaluate the Effect of Secukinumab 300 mg s.c. Administered During 52 Weeks to Patients Suffering From New-onset Moderate to Severe Plaque Psoriasis as Early Intervention Compared to Standard Treatment With Narrow-band UVB (STEPIn Study)
Brief Summary: The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).


Options:
A: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
B: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
C: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter STudy to Evaluate the Effect of Secukinumab 300 mg s.c. Administered During 52 Weeks to Patients Suffering From New-onset Moderate to Severe Plaque Psoriasis as Early Intervention Compared to Standard Treatment With Narrow-band UVB (STEPIn Study)
Brief Summary: The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).


Options:
A: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
B: Arm Label: Active Treatment (10 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (10 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID
C: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
D: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter STudy to Evaluate the Effect of Secukinumab 300 mg s.c. Administered During 52 Weeks to Patients Suffering From New-onset Moderate to Severe Plaque Psoriasis as Early Intervention Compared to Standard Treatment With Narrow-band UVB (STEPIn Study)
Brief Summary: The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).


Options:
A: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
B: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A
D: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease
Brief Summary: Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis.

Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require dialysis. It works by blocking a hormone (aldosterone) in your body that causes high blood pressure and can damage the heart. Although spironolactone is very effective in patients that do not require dialysis, we do not know if spironolactone is effective in dialysis patients. Our research will help determine if spironolactone reduces heart failure and heart related deaths in dialysis patients.

The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in patients that require dialysis.


Options:
A: Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone
B: Arm Label: Placebo Oral Tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Arm Label: Spironolactone 25 MG Tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone 25Mg Tablet | Intervention Type: DRUG; Name: Spironolactone 25Mg Tablet; Assigned to Arm(s): Spironolactone 25 MG Tablet | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo Oral Tablet
C: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): spironolactone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
Brief Summary: The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 5 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day, Brivaracetam 5 mg/day, Brivaracetam 50 mg/day
B: Arm Label: Brivaracetam; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam
C: Arm Label: Brivaracetam (BRV) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam (BRV) 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Lorazepam (LZP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam (BRV) 100 mg, Brivaracetam (BRV) 200 mg | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam (LZP)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Brivaracetam 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 50 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Arm Label: Brivaracetam 100 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Brivaracetam | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 20 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 50 mg/day | Intervention Type: DRUG; Name: Brivaracetam; Assigned to Arm(s): Brivaracetam 100 mg/day

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Individualized Perioperative Hemodynamic Goal-directed Therapy in Major Abdominal Surgery (iPEGASUS-trial) - A Multi-center, Prospective, Randomized Trial
Brief Summary: To evaluate the impact of perioperative, algorithm driven, hemodynamic therapy based on individualized fluid and cardiac output optimization on postoperative moderate and severe complications in patients undergoing major abdominal surgery including visceral, urological, and gynecological operations.

In the proposed study, hemodynamic therapy is tailored individually to each patient, based on individual preload optimization by the functional parameter "pulse pressure variation (PPV)" and based on an individually titrated goal of cardiac index. The proposed study therefore further develops the concept of hemodynamic goal-directed therapy to individually set goals and is designed to assess its impact on morbidity and mortality.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13% | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Fluid titrated at the discretion of the attending anesthesiologist | Intervention Type: OTHER; Name: Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Fluid titrated at the discretion of the attending anesthesiologist; Assigned to Arm(s): Control
B: Arm Label: Goal directed fluid therapy using esophageal doppler monitor; Type: ACTIVE_COMPARATOR; Interventions: Device: Esophageal Doppler Monitor | Arm Label: Fluid therapy using standard management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Esophageal Doppler Monitor; Assigned to Arm(s): Goal directed fluid therapy using esophageal doppler monitor
C: Arm Label: Individualized Goal Directed Therapy (iGDT); Type: EXPERIMENTAL; Interventions: Procedure: Individualized Goal Directed Therapy | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Control Group | Intervention Type: PROCEDURE; Name: Individualized Goal Directed Therapy; Assigned to Arm(s): Individualized Goal Directed Therapy (iGDT) | Intervention Type: PROCEDURE; Name: Control Group; Assigned to Arm(s): Control
D: Arm Label: Automated fluid management system (Closed-loop system); Type: EXPERIMENTAL; Interventions: Device: Closed loop automated System (LIR®: learning intravenous resuscitator) | Arm Label: Current practice manual fluid management; Type: SHAM_COMPARATOR; Interventions: Device: manual current practice by anesthesiologist team | Intervention Type: DEVICE; Name: Closed loop automated System (LIR®: learning intravenous resuscitator); Assigned to Arm(s): Automated fluid management system (Closed-loop system) | Intervention Type: DEVICE; Name: manual current practice by anesthesiologist team; Assigned to Arm(s): Current practice manual fluid management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mobile Health Strategies for Veterans With Coronary Heart Disease
Brief Summary: The purpose of this study is to determine whether text messages/messaging (TM) or a mobile application (app), compared with an educational website-control provided to all Veterans, can improve adherence to antiplatelet therapy among patients following acute coronary syndrome or percutaneous coronary intervention (ACS/PCI).


Options:
A: Arm Label: Medication text message; Type: EXPERIMENTAL; Interventions: Behavioral: Text message reminder for medication adherence | Arm Label: Exercise text message; Type: EXPERIMENTAL; Interventions: Behavioral: Text message reminder for exercise regimen | Arm Label: Usual care, medication adherence; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care, exercise regimen; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text message reminder for medication adherence; Assigned to Arm(s): Medication text message | Intervention Type: BEHAVIORAL; Name: Text message reminder for exercise regimen; Assigned to Arm(s): Exercise text message
B: Arm Label: Text Message Group; Type: EXPERIMENTAL; Interventions: Behavioral: Text Message, Other: Website | Arm Label: Application Group; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile Application, Other: Website | Arm Label: Website-Control; Type: EXPERIMENTAL; Interventions: Other: Website | Intervention Type: BEHAVIORAL; Name: Text Message; Assigned to Arm(s): Text Message Group | Intervention Type: BEHAVIORAL; Name: Mobile Application; Assigned to Arm(s): Application Group | Intervention Type: OTHER; Name: Website; Assigned to Arm(s): Application Group, Text Message Group, Website-Control
C: Arm Label: Txt2Prevent; Type: EXPERIMENTAL; Interventions: Behavioral: Txt2Prevent | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Txt2Prevent; Assigned to Arm(s): Txt2Prevent
D: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Medication-taking reminders & educational materials | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Educational materials | Intervention Type: BEHAVIORAL; Name: Medication-taking reminders & educational materials; Assigned to Arm(s): Experimental group | Intervention Type: BEHAVIORAL; Name: Educational materials; Assigned to Arm(s): Control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Retention in PMTCT/MNCH Services and Facility Delivery in Tabora, Tanzania
Brief Summary: The goal of this proposed intervention study is to increase the proportion of HIV positive and HIV negative pregnant women who deliver in a facility, the proportion of HIV exposed infants (HEI) who receive nevirapine (NVP) within 48 hours of delivery, and the proportion of HEI who are bled for HIV polymerase chain reaction (PCR) deoxyribonucleic acid (DNA) testing within 8 weeks of age.


Options:
A: Arm Label: Motivational SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational SMS | Arm Label: Travel Voucher; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational SMS, Behavioral: Travel Voucher | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational SMS; Assigned to Arm(s): Motivational SMS, Travel Voucher | Intervention Type: BEHAVIORAL; Name: Travel Voucher; Assigned to Arm(s): Travel Voucher
B: Arm Label: Crowdsourced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Crowdsourced materials | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: Crowdsourced materials; Assigned to Arm(s): Crowdsourced intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Two-way SMS dialogue; Type: EXPERIMENTAL; Interventions: Behavioral: Two-way SMS Dialogue | Arm Label: One-way SMS Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: One-way SMS Messaging | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Two-way SMS Dialogue; Assigned to Arm(s): Two-way SMS dialogue | Intervention Type: BEHAVIORAL; Name: One-way SMS Messaging; Assigned to Arm(s): One-way SMS Messaging
D: Arm Label: Clinic group 1; Type: EXPERIMENTAL; Interventions: Behavioral: mHealth messaging | Arm Label: Clinic group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Transport Payments | Arm Label: Clinic group 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: mHealth messaging; Assigned to Arm(s): Clinic group 1 | Intervention Type: BEHAVIORAL; Name: Transport Payments; Assigned to Arm(s): Clinic group 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Retention in PMTCT/MNCH Services and Facility Delivery in Tabora, Tanzania
Brief Summary: The goal of this proposed intervention study is to increase the proportion of HIV positive and HIV negative pregnant women who deliver in a facility, the proportion of HIV exposed infants (HEI) who receive nevirapine (NVP) within 48 hours of delivery, and the proportion of HEI who are bled for HIV polymerase chain reaction (PCR) deoxyribonucleic acid (DNA) testing within 8 weeks of age.


Options:
A: Arm Label: Telephone reminder; Type: EXPERIMENTAL; Interventions: Other: Telephone reminder | Arm Label: Text Message reminder; Type: EXPERIMENTAL; Interventions: Other: Text Message reminder | Arm Label: Control: Telephone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control: Text Message; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone reminder; Assigned to Arm(s): Telephone reminder | Intervention Type: OTHER; Name: Text Message reminder; Assigned to Arm(s): Text Message reminder
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity; Type: OTHER; Interventions: Other: Telephone-based breastfeeding peer counseling | Arm Label: High Intensity; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone-based breastfeeding peer counseling | Intervention Type: OTHER; Name: Telephone-based breastfeeding peer counseling; Assigned to Arm(s): High Intensity, Low Intensity
C: Arm Label: Clinic group 1; Type: EXPERIMENTAL; Interventions: Behavioral: mHealth messaging | Arm Label: Clinic group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Transport Payments | Arm Label: Clinic group 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: mHealth messaging; Assigned to Arm(s): Clinic group 1 | Intervention Type: BEHAVIORAL; Name: Transport Payments; Assigned to Arm(s): Clinic group 2
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: EpxBreastfeeding, Other: Baby book survey | Arm Label: Control; Type: OTHER; Interventions: Other: Baby book survey | Intervention Type: OTHER; Name: EpxBreastfeeding; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Baby book survey; Assigned to Arm(s): Control, Intervention

Answer: C